Inactive Instrument

Cannabis Science, Inc.

Equities

Biotechnology & Medical Research

Cannabis To Seek Acquisitions

March 25, 2019 at 12:00 am EDT

Cannabis Science, Inc. (OTCPK:CBIS) will look for acquisition opportunities. Cannabis Chief Executive Officer Raymond C. Dabney said, "Cannabis Science intends to create a vertically integrated, international organization, through investing in the organic growth and development of the Company's operational capabilities, as well as through strategic acquisitions."

Latest news about Cannabis Science, Inc.

GBX International Group Inc. agreed to Spin-Off Cannabis Science, Inc.	23-04-20	CI
Cannabis Science Inc. Successfully Launches its $CSI Cannabis Science Coin for its CSi-EDP Utility Project Valuation Tracking	21-08-10	CI
Thermic Sciences International signed a share exchange agreement to acquire Cannabis Science, Inc.	21-03-30	CI
NHS Industries, Ltd. and Cannabis Science, Inc. Agree to Terminate the Previously Announced Joint Venture Agreement	19-09-27	CI
Cannabis Science Partners With NHS Industries to Launch the CBIS CDN Economic Development Plan	19-08-28	CI
Cannabis Science Successfully Moves Operations to The Netherlands and Completes Shut Down of All Cannabis Science Europe GmbH Germany Operations	19-08-05	CI
Cannabis Science, Inc. Appoints Sulma Mohammed to its Scientific Advisory Board	19-06-03	CI
Cannabis Science, Inc. and Dana-Farber Cancer Institute, Inc. Sign New Research Agreement to Investigate Proprietary Extract from Justicia Plant	19-05-20	CI
Cannabis Science Announces Formation of Cannabis Science Canada Inc	19-03-25	CI
Cannabis To Seek Acquisitions	19-03-25	CI
Cannabis Science, Inc. cancelled the acquisition of Novus Beverage Solutions Corp.	19-03-13	CI
Cannabis Science, Inc. Announces Intends to Expand the Scope of its Sponsored Research in Nigeria to Include Neurological Conditions, Including Post-Traumatic Stress Disorder	19-02-25	CI
RCD Chooses Cannabis Science, Inc.'s www.iCannabinoid.com to Interact and Inform on All Company Projects, Drug Development, and All RCD Initiatives	19-01-23	CI
Cannabis Science, Inc Appoints Melvin Foote to its Newly-Restructured International Government Affairs Advisory Board	18-10-24	CI
Cannabis Science, Inc. Appoints Joe Wilson to its International Government Affairs Board	18-09-28	CI
Cannabis Science, Inc. Appoints Dr. Jermane Bond to its Scientific Advisory Board	18-09-21	CI
Cannabis Science, Inc. Appoints New Leadership for its Scientific Advisory and International Government Affairs Advisory Boards	18-09-12	CI
Cannabis Science Seeks Acquisitions	18-09-12	CI
Cannabis Science, Inc. Announces Demise of Allen Herman, Chief Medical Officer and Ronald V. Dellums, President of International Government Affairs Board	18-08-08	CI
Cannabis Science, Inc. and FSO NAC Sign for New 100-Acre Property in Minden, Nevada as the Industrial Hemp Research Projects in Nevada Continue to Flourish for the Group	18-07-24	CI
Cannabis Science, Inc. Announces the Immediate Launch of A New 40-Acre Industrial Hemp Research and Development Project in Nevada	18-07-10	CI
Cannabis Science, Global Health Catalyst, Elpasso Farms (South Africa), and American States University Partner to Strengthen Africa’S Economic and Healthcare Infrastructure	18-07-09	CI
Cannabis Science, Inc. Appoints Brylyne Chitsunge to its Scientific Advisory Board	18-06-05	CI
Cannabis Science Announces Opening of the First CBIS Cali Rx Location on Ventura Blvd, in Sherman Oaks, California	18-04-23	CI
Cannabis Science, Inc. entered into an agreement to acquire Novus Beverage Solutions Corp.	18-04-04	CI

Chart Cannabis Science, Inc.

Duration

Period

More charts

Company Profile

Cannabis Science, Inc. is engaged in medical marijuana research and development. The Company works on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. The Company is involved in the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance. The Company focuses on the development of governmentally approved pharmaceuticals, including CS-TATI1, CS-S/BCC-1 and neurological therapy under study or development. The Company's subsidiaries include Cannabis Science BV and Cannabis Science International Holding BV.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs